Bivi stock forecast 2025 momentum traders see upside in "BIVI

Momentum traders see upside in "BIVI stock forecast 2025" if biotech market indices maintain a positive trajectory. Volume spikes in August 2024 hinted at speculative pre-positioning. Watching for continuation patterns in Q4 could provide early entry signals ahead of key announcements. So, the natural question for BioVie ( NASDAQ:BIVI ) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn. On July 17, 2025, BioVie Inc. expanded its Board of Directors from four to six members, appointing Amy S. Chappell, MD, FAAN, and Kameel D. Farag. These seasoned leaders bring significant expertise in neuroscience drug development and corporate finance, which is expected to support BioVie’s mission as it advances its drug candidate bezisterim through Phase 2 trials for early Parkinson’s disease and long COVID, and plans further clinical development for Alzheimer’s disease and ascites programs. The appointments come amid growing momentum for BioVie, which recently presented promising data on bezisterim’s potential at the World Aging and Rejuvenation Conference and initiated its Phase 2 long COVID trial. Recent insider buying activity supports a positive slant to the "BIVI stock forecast 2025". Historically, insider purchases in biotech often precede important corporate developments, which could be interpreted as confidence in upcoming trial outcomes.